Ledipasvir–sofosbuvir for treating chronic hepatitis C

Equality Impact Assessment (Guidance development) (PDF 174 KB)

Final appraisal determination

Committee papers (PDF 1.23 MB)

Final appraisal determination document (PDF 823 KB)

Appraisal consultation 2

Appraisal consultation document 2 (PDF 441 KB)

Committee papers 2 information

Committee papers 2 (PDF 5.35 MB)

Appraisal consultation 1

Appraisal consultation document 1 (PDF 192 KB)

Committee papers 1 information

Committee papers 1 (PDF 11.5 MB)

Hepatitis C (chronic) - ledipasvir-sofosbuvir: final scope (PDF 109 KB)

Hepatitis C (chronic) - ledipasvir-sofosbuvir: final matrix (PDF 105 KB)

Hepatitis C (chronic) - ledipasvir-sofosbuvir: response to consultee and commentator comments on the draft scope and provisional matrix (PDF 291 KB)

Hepatitis C (chronic) - ledipasvir-sofosbuvir: equality impact assessment - scoping (PDF 64 KB)

Hepatitis C (chronic) - ledipasvir-sofosbuvir: draft scope for consultation (pre-referral) - March 2014 (PDF 111 KB)

Hepatitis C (chronic) - ledipasvir-sofosbuvir: provisional matrix (pre-referral) - March 2014 (PDF 107 KB)